Arcus Biosciences - RCUS Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RCUS shares.
View RCUS analyst ratings or view top-rated stocks.

7 brokers have issued 1-year price objectives for Arcus Biosciences' stock. Their RCUS share price forecasts range from $36.00 to $60.00. On average, they predict the company's stock price to reach $47.13 in the next twelve months. This suggests a possible upside of 82.0% from the stock's current price.
View analysts price targets for RCUS or view top-rated stocks among Wall Street analysts.

Arcus Biosciences' stock was trading at $40.47 at the start of the year. Since then, RCUS shares have decreased by 36.0% and is now trading at $25.89.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our RCUS earnings forecast.

Arcus Biosciences, Inc. (NYSE:RCUS) announced its earnings results on Wednesday, August, 3rd. The company reported ($0.93) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.93). The business earned $26.76 million during the quarter, compared to analysts' expectations of $21 million. Arcus Biosciences had a trailing twelve-month return on equity of 9.12% and a net margin of 16.34%. During the same quarter in the prior year, the company earned ($1.09) EPS.

4 employees have rated Arcus Biosciences Chief Executive Officer Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among the company's employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD).

(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.

Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."

Arcus Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (6.15%), FMR LLC (4.60%), Pictet Asset Management SA (2.65%), Goldman Sachs Group Inc. (1.35%), Northern Trust Corp (0.94%) and UBS Asset Management Americas Inc. (0.62%). Insiders that own company stock include Carolyn C Tang, Carolyn C Tang, Gilead Sciences Inc, Jennifer Jarrett, Juan C Jaen, Kathryn E Falberg, Robert C Goeltz II, Terry J Rosen, William Grossman and Yasunori Kaneko.
View institutional ownership trends.

Shares of RCUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of RCUS stock can currently be purchased for approximately $25.89.

Arcus Biosciences (NYSE:RCUS) has a market capitalization of $1.87 billion and generates $382.88 million in revenue each year. The company earns $52.83 million in net income (profit) each year or $0.71 on an earnings per share basis.

The company employs 366 workers across the globe.

Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for the company is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com.